Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 4/20 | 0.65 |
| ▸ | SLC40A1 | Q9NP59 | 12/20 | 0.63 |
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | NFKBIA | P25963 | 1/20 | 0.59 |
| ▸ | RELA | Q04206 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14919762 | 0.84 | MEN1 (0.73) | MCL1SLC40A1ATMMEN1KMT2A | |
| SCHEMBL19040920 | 0.79 | PKLR (0.65) | — | |
| SCHEMBL16286079 | 0.78 | SLC40A1 (0.78) | SLC40A1MEN1KMT2ANFKBIARELA | |
| SCHEMBL22315265 | 0.78 | ATM (0.74) | SLC40A1ATMMEN1KMT2A | |
| SCHEMBL2702515 | 0.77 | PKLR (0.63) | — | |
| SCHEMBL11973115 | 0.77 | SLC40A1 (0.83) | SLC40A1MEN1KMT2ANFKBIARELA | |
| SCHEMBL414126 | 0.77 | SLC40A1 (1.00) | SLC40A1MEN1KMT2ANFKBIARELA | |
| SCHEMBL1507919 | 0.76 | SLC40A1 (0.76) | SLC40A1ATMMEN1KMT2ANFKBIA | |
| SCHEMBL30854809 | 0.76 | SLC40A1 (0.76) | SLC40A1ATMMEN1KMT2ANFKBIA | |
| SCHEMBL30854823 | 0.76 | SLC40A1 (0.70) | SLC40A1ATMMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470821-B2 | PDE4B inhibitors and uses therefor | PLEXXIKON INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8470821-B2 | PDE4B inhibitors and uses therefor | PLEXXIKON INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20090286793-A1 | PDE4B INHIBITORS AND USES THEREFOR | PLEXXIKON, INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090286793-A1 | PDE4B INHIBITORS AND USES THEREFOR | PLEXXIKON, INC. | 2009-11-19 | — | — | US | disclosed |
| US-7585859-B2 | PDE4B inhibitors and uses therefor | PLEXXIKON, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| US-7585859-B2 | PDE4B inhibitors and uses therefor | PLEXXIKON, INC. (US) | 2009-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286793-A1 | PDE4B INHIBITORS AND USES THEREFOR | PDE4B, PDE7B, PDE4A | MCL1 4509/4885SLC40A1 4638/4885ATM 2379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.